Physician profile
John Suder
NPI 1336637990
$2,418.30
in general payments reported to CMS, 2019-2025
15 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $416 · 2023: $825 · 2024: $643 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.94 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $824.45 | 2022-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $313.85 | 2023-2024 | Andexxa, Fasenra, Bevespi Aerosphere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.41 | 2022-2025 | |
| Abbvie INC. | $198.53 | 2023-2025 | Avycaz |
| Janssen Pharmaceuticals, INC | $152.49 | 2022 | |
| Digestive Care, INC. | $133.57 | 2025 | Pertzye |
| Pulmonx Corporation | $130.04 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Amgen INC. | $93.23 | 2024 | Tezspire |
| Mylan Specialty L.P. | $75.72 | 2022 | |
| Merck Sharp & Dohme LLC | $62.74 | 2023-2025 | Zerbaxa |
| La Jolla Pharmaceutical Company | $54.49 | 2024-2025 | Giapreza |
| United Therapeutics Corporation | $46.62 | 2024 | Tyvaso |
| Shionogi INC | $34.60 | 2023 | Fetroja |
| Astellas Pharma US INC | $25.26 | 2024 | Cresemba |
| Baxter Healthcare | $18.30 | 2025 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Suder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.